Samuel D. Wright

Active 1982–2023

119
Papers
33,987
Citations
96
h-index
119
i10-index

Citations

Citations per year for Samuel D. Wright1982: 2 citations1983: 21 citations1984: 31 citations1985: 42 citations1986: 53 citations1987: 83 citations1988: 107 citations1989: 163 citations1990: 228 citations1991: 226 citations1992: 288 citations1993: 358 citations1994: 309 citations1995: 299 citations1996: 317 citations1997: 204 citations1998: 394 citations1999: 413 citations2000: 374 citations2001: 370 citations2002: 452 citations2003: 382 citations2004: 342 citations2005: 293 citations2006: 290 citations2007: 252 citations2008: 259 citations2009: 220 citations2010: 202 citations2011: 238 citations2012: 268 citations2013: 254 citations2014: 229 citations2015: 218 citations2016: 233 citations2017: 231 citations2018: 233 citations2019: 594 citations2020: 660 citations2021: 659 citations2022: 524 citations2023: 412 citations2024: 485 citations2025: 254 citations2026: 5 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,255 citing papers, 33% of this breakdownChina: 1,199 citing papers, 9.3% of this breakdownGermany: 918 citing papers, 7.1% of this breakdownUnited Kingdom: 832 citing papers, 6.5% of this breakdownFrance: 494 citing papers, 3.8% of this breakdownJapan: 476 citing papers, 3.7% of this breakdownCanada: 456 citing papers, 3.5% of this breakdownItaly: 403 citing papers, 3.1% of this breakdownNetherlands: 379 citing papers, 2.9% of this breakdownAustralia: 329 citing papers, 2.6% of this breakdownSwitzerland: 276 citing papers, 2.2% of this breakdownSweden: 236 citing papers, 1.8% of this breakdown
0%33%Other 20.5%

Fields

  • Medicine42.2%
  • Biochemistry, Genetics and Molecular Biology25.6%
  • Immunology and Microbiology24.1%
  • Neuroscience2.9%
  • Nursing1.3%
  • Agricultural and Biological Sciences1%
  • Other2.9%

Topics

  • Immune Response and Inflammation6.3%
  • Inflammasome and immune disorders4.6%
  • Cell Adhesion Molecules Research3.4%
  • Cholesterol and Lipid Metabolism2.5%
  • Atherosclerosis and Cardiovascular Diseases2.3%
  • Adipokines, Inflammation, and Metabolic Diseases2%
  • Other78.9%

Coauthors

All papers

Open in search
  1. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

    Authors: , , , , , , , , , , , , , , , , , - Nature 2010 cited by 3,992

  2. (d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G

    Authors: , , , , , , , , , , , , , , , , , - Journal of Biological Chemistry 2005 cited by 651

  3. CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein

    Authors: , , , , - Science 1990 cited by 4,025

  4. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Immunology 2013 cited by 461

  5. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2016 cited by 362

  6. A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Journal of Immunology 2017 cited by 331

  7. Role of GPR81 in lactate-mediated reduction of adipose lipolysis

    Authors: , , , , , , , , - Biochemical and Biophysical Research Communications 2008 cited by 296

  8. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue

    Authors: , , , , , , , , , , - Journal of Hepatology 2023 cited by 64

  9. Structure and Function of Lipopolysaccharide Binding Protein

    Authors: , , , , , , , - Science 1990 cited by 1,690

  10. 27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells

    Authors: , , , , , , , - Journal of Biological Chemistry 2001 cited by 575

  11. The Farnesoid X Receptor Controls Gene Expression in a Ligand- and Promoter-selective Fashion

    Authors: , , , , , , , - Journal of Biological Chemistry 2004 cited by 213

  12. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

    Authors: , , , , , , , , - The Journal of Experimental Medicine 1994 cited by 753

  13. Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux

    Authors: , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2013 cited by 124

  14. CSL112 Enhances Biomarkers of Reverse Cholesterol Transport After Single and Multiple Infusions in Healthy Subjects

    Authors: , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2014 cited by 113

  15. ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

    Authors: , , , , , , , , , , , , , , - Current Atherosclerosis Reports 2022 cited by 28

  16. CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen.

    Authors: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1991 cited by 280

  17. Lithocholic Acid Decreases Expression of Bile Salt Export Pump through Farnesoid X Receptor Antagonist Activity

    Authors: , , , , , , , , - Journal of Biological Chemistry 2002 cited by 192

  18. Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John F. Paolini, M. Gerard Waters, Andrew Plump - Science Translational Medicine 2012 cited by 127

  19. Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112

    Authors: , , , , , , , , , - Circulation Research 2016 cited by 102

  20. Discovery of a potent and selective small molecule hGPR91 antagonist

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Bioorganic & Medicinal Chemistry Letters 2011 cited by 76

  21. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

    Authors: , , , , , , , , , , , , - Journal of Cardiovascular Pharmacology and Therapeutics 2022 cited by 19

  22. Soluble CD14 participates in the response of cells to lipopolysaccharide.

    Authors: , , , , , , , - The Journal of Experimental Medicine 1992 cited by 693

  23. Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering

    Authors: , , , , , , , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2001 cited by 414

  24. Regulation of the angiopoietin-like protein 3 gene by LXR

    Authors: , , , , , , - Journal of Lipid Research 2003 cited by 124